<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619875</url>
  </required_header>
  <id_info>
    <org_study_id>K008-117</org_study_id>
    <nct_id>NCT04619875</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Assess the Effect of Increasing Intake Amounts of Two Novel Glycans on the Gut Microbiota of Healthy Subjects</brief_title>
  <official_title>A Randomized, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of Increasing Intake Amounts of Two Novel Glycans on the Gut Microbiota of Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaleido Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaleido Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory, randomized, open label study aims to explore the safety, tolerability,&#xD;
      pharmacokinetics, and effects of increasing intake amounts of two novel glycans on the gut&#xD;
      microbiota of healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2017</start_date>
  <completion_date type="Actual">November 21, 2017</completion_date>
  <primary_completion_date type="Actual">November 21, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by incidence of adverse advents</measure>
    <time_frame>Day -8 to Day 35</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability as assessed by Gastrointestinal Tolerability Questionnaire (GITQ) score</measure>
    <time_frame>Day -8 to Day 35</time_frame>
    <description>The GITQ is an assessment of the frequency and severity of GI symptoms, eg., gas, abdominal pain, calculated on a scale from 0 (None/Not applicable) to a maximum score of 60 (Severe/Much more than usual) for all questions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability as assessed by change in Bristol Stool Scale (BSS)</measure>
    <time_frame>Day -8 to Day 35</time_frame>
    <description>The BSS is an assessment of stool consistency on a scale from 1 (separate hard lumps, like nuts, hard to pass) through 7 (watery, no solid pieces, entirely liquid)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lactulose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KB5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SG1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>KB5</intervention_name>
    <description>KB5, a novel glycan, is a Kaleido laboratory code for KB174</description>
    <arm_group_label>KB5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SG1</intervention_name>
    <description>SG1 is a novel glycan</description>
    <arm_group_label>SG1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>Lactulose is a synthetic dissacharide</description>
    <arm_group_label>Lactulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        To be eligible for inclusion, the patient must fulfill all of the following criteria at&#xD;
        screening:&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
          -  Willing to provide multiple stool samples&#xD;
&#xD;
          -  Be male or female, ≥18 and ≤65 years of age&#xD;
&#xD;
          -  Have a body mass index ≥20 and &lt;40 kg/m2&#xD;
&#xD;
          -  No current renal, hepatic or metabolic disease, significant dyslipidemia, or&#xD;
             infection.&#xD;
&#xD;
          -  Willing to adhere to dietary requirements as stated in the protocol.&#xD;
&#xD;
          -  Willing to continue his/her normal diet and exercise routine.&#xD;
&#xD;
          -  Willing to continue taking any current supplements and vitamins, (with the exception&#xD;
             of prebiotic or probiotic supplements) that the subject is currently taking, for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Negative urine drug screen&#xD;
&#xD;
          -  If subject is female, have a negative urine pregnancy test at Screening and be willing&#xD;
             to engage in method of contraception until completion of the study&#xD;
&#xD;
        Patients will be excluded from the study if they meet any of the following criteria at&#xD;
        screening:&#xD;
&#xD;
          -  Currently taking probiotic or prebiotic dietary supplements, or have taken them in the&#xD;
             past 28 days (prior to Screening Visit), or unwilling to avoid probiotic or probiotic&#xD;
             dietary supplements for the duration of the study&#xD;
&#xD;
          -  Currently taking, or have taken in the last 7 days, drugs or other compounds to&#xD;
             modulate gastrointestinal motility&#xD;
&#xD;
          -  Recent history (within six weeks of Screening) of the following conditions requiring&#xD;
             medical attention or treatment, including over-the-counter medications: constipation,&#xD;
             diarrhea, and/or acute GI illness.&#xD;
&#xD;
          -  Systemic antibiotics taken within the previous three months (prior to Screening&#xD;
             Visit).&#xD;
&#xD;
          -  History of or active inflammatory bowel disease&#xD;
&#xD;
          -  History of or active irritable bowel syndrome&#xD;
&#xD;
          -  History of or active autoimmune disease&#xD;
&#xD;
          -  History of or active GI malignancy&#xD;
&#xD;
          -  Established pre-diabetic status (eg, multiple fasting blood glucose measurements 100&#xD;
             to 125 mg/dL inclusive, or history of failed glucose tolerance tests) and as assessed&#xD;
             by HbA1c test&#xD;
&#xD;
          -  Have used an investigational drug or device within 30 dyas of study or be concurrently&#xD;
             enrolled in another investigational drug or device study within 30 days of the study&#xD;
             (prior to the Screening Visit)&#xD;
&#xD;
          -  Subject is a current smoker&#xD;
&#xD;
          -  Subject has a history of drug and/or alcohol abuse&#xD;
&#xD;
          -  Contraindications, sensitivity, or known allergy to the use of the study product(s) or&#xD;
             their components&#xD;
&#xD;
          -  Have used an investigational drug or device within 30 days of the study or be&#xD;
             concurrently enrolled in another investigational drug or device study within 30 days&#xD;
             of the study (prior to the Screening Visit)&#xD;
&#xD;
          -  Individuals who, in the opinion of the PI, are considered to be poor attendees or&#xD;
             unlikely for any reason to be able to comply with the study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Wingertzahn, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kaleido Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biofortis</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <zip>60101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Kaleido</keyword>
  <keyword>Kaleido Biosciences</keyword>
  <keyword>Oligosaccharide</keyword>
  <keyword>Glycan</keyword>
  <keyword>Microbiome Metabolic Therapy</keyword>
  <keyword>KB174</keyword>
  <keyword>KB5</keyword>
  <keyword>SG1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

